Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection

By I. Hung, K. K. To, Cheuk-Kwong Lee, Kar-Lung Lee, Kenny Chan, W. Yan, R. Liu, C. Watt, W. Chan, K. Lai and 13 more. Clinical Infectious Diseases, 2011

710 citations recorded by the source corpus.

Treatment of severe pandemic influenza A(H1N1) 2009 virus infection with convalescent plasma suppressed the viral load and cytokine response, thereby reducing the subsequent risk of complication and death. Further studies by double-blind randomized controlled trial of plasma treatment in these patients are warranted.

Subfields: Epidemiology, Immunology

View Paper: https://www.semanticscholar.org/paper/3bc108df08888ac75bb6884617f55398bfc079d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. F. Sallusto
2. S. Perlman
3. Ralph S. Baric
4. A. Lanzavecchia

In Immunology

1. F. Sallusto
2. A. Lanzavecchia
3. Rafi Ahmed
4. Bali Pulendran
5. V. Schirrmacher

Citations in the corpus

• Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus (2015, positive): “This has been demonstrated for infections including Spanish influenza pneumonia during 1918 1919 (18), SARS-CoV (19), H5N1 influenza A virus (20), and more recently severe H1N1 influenza A virus infection (21).”
• The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis (2014, methodology): “Data on 1327 patients from 6 case studies [23–28], 20 case series [8, 17, 20, 29–45], 2 case-comparison studies [46, 47], and 1 prospective cohort [48] were included.”
• The cytokine storm and COVID‐19 (2020, result): “This approach has demonstrated promising results in the treatment of SARS and influenza.(80,81) However, a Cochrane systematic review revealed weak evidence on the effectiveness and safety of this therapy for patients with COVID‐19.”
• The convalescent sera option for containing COVID-19. (2020, neutral): “In the 2009–2010 H1N1 influenza virus pandemic, convalescent serum antibody preparations obtained by apheresis were used to treat individuals with severe H1N1 2009 infection requiring intensive care (14).”
• Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence (2020, positive): “A prospective cohort study by Hung and colleagues showed that for patients with pandemic H1N1 influenza virus infection in 2009, the relative risk of death was significantly lower in patients treated with convalescent plasma [61] .”
• Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset (2015, background): “However, this is also not readily available, as its preparation requires the recruitment of a large number of convalescent patients with high serum antibody titers.”
• Deployment of convalescent plasma for the prevention and treatment of COVID-19. (2020, positive): “…rabies) and/or treatment for a myriad of infectious diseases (e.g., influenza, Argentine hemorrhagic fever, SARS-CoV, Middle East respiratory syndrome [MERS], Ebola), favorably affecting a range of laboratory (e.g., viral loads, cytokine responses) and clinical outcomes (notably mortality) (6–12).”